Background
Tuberculosis (TB) is a disease that produces several million deaths annually. With the appearance of multi drug resistant microbial strains of Mycobacterium tuberculosis, innovations in TB drug discovery and evolving strategies to bring new agents with best performance is an essential investigation. Taking this into account, there is a pressing need to develop new and more effective anti tubercular agents. The coordination of metal with organic drugs is a promising strategy that has been successful in many cases with different pharmacological activities. The emergence of new cases and the adverse effects of first and second-line antituberculosis drugs have led to renewed research interest in metal drug complexes in the hope of discovering new antituberculosis drugs. The aim of the present study is to assess the antituberculosis activity of Ni (II) and Cu (II) complexes of polymer ligand poly (3-nitrobenzylidene-1-naphthylamine-co-methacrylic acid).
Methods
Antituberculosis activities of the ligand and its complexes were assessed against M. tuberculosis H37 Rv strain by microplate alamar blue assay (MABA) method using pyrazinamide as standard.
Anzeige
Results
The minimum inhibitory concentration values of the ligand and its complexes on comparison with standard (pyrazinamide; 4 µg/mL) indicate that the complexes exhibit promising antituberculosis activity. Cu (II) complex shows more activity (10 µg/ mL) followed by Ni (II) complex (20µg/ mL) and ligand (35 µg/ mL).
Conclusion
Among the synthesized compounds, the Cu (II) complex may be used as therapeutic substitute in the treatment of tuberculosis by replacing the routine drugs.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.